A paper outlining MHRA’s intentions to make it quicker and easier to get rare disease therapies tested, manufactured and approved in the UK.
Similar Posts
Official Statistics: Quarterly reports on the import of unlicensed medicines
Details and statistics on the import of unlicensed medicines from March 2014 onwards.
Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.
Notice: Medicines: terminated and cancelled manufacturing and wholesale dealer licences
UK companies who have their licence to manufacture or wholesale medicines terminated and cancelled.
MHRA issues new guidance for people using mental health apps and technologies
New online resources will help the public, parents, carers and health, social care and education professionals understand what safe, effective digital mental health technologies look like in practice.
MHRA announces proposals to improve access to world’s best medical devices for patients and to boost economic growth in Britain’s med tech sector
The MHRA has now published the government’s response to its public consultation on future routes to market for medical devices – designed to modernise regulation
Brensocatib licensed as the first medicine specifically designed to treat non-cystic fibrosis bronchiectasis in patients 12 years and older
As with any medicine, the MHRA will keep the safety and effectiveness of brensocatib under close review.